Phrontline Biopharma: Valuation, Funding & Investors
Phrontline Biopharma is a biotechnology company dedicated to the research and development of next-generation ADCs. Founded in 2022 by a team of seasoned industry veterans with deep and complementary experience in ADC drug discovery and development, Phrontline has built a globally competitive platform for bispecific and dual-payload ADCs. The company has established a robust pipeline of innovative candidates spanning preclinical to early clinical stages and is committed to advancing a new paradigm in precision oncology through scientific innovation and to bringing transformative therapies to patients worldwide.
Leadership & Board
- Current Number of Employees
- 11
- Current LinkedIn Followers
- 318
Latest Estimated Valuation
- Total Amount Raised
- $120M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $60M
- Latest Funding Round
- Series A
Employee Trend
Phrontline Biopharma had 11 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Phrontline Biopharma had 318 followers as of November 16, 2026. The number of followers increased by 4 (1.27%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 25, 2025 | Series A | $60.00M | ― |
| Nov 25, 2025 | Investment | $60.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Decheng Capital | Series A |
| Lapam Investment | Series A |
| Samsung Venture Investment Corporation | Series A |
| Guofang Innovation | Series A |
| Hankang Venture Capital | Series A |
| Songqing Capital | Series A |
| Jifeng Ventures | Series A |
| Sino Biopharmaceutical Limited | Series A |
Similar Companies
A snapshot of private companies similar to Phrontline Biopharma, helping you discover and navigate related company profiles.
Related News and Analysis








